Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On January 23, 2018, Five Prime Therapeutics, Inc. (“Five Prime”) filed with the Securities and Exchange Commission (the “SEC”) a preliminary prospectus supplement in connection with a proposed public offering of shares of Five Prime’s common stock. The preliminary prospectus supplement contains the following preliminary unaudited financial results of Five Prime under the heading “Preliminary Financial Results”:

We are currently finalizing our financial results for the fiscal year ended December31, 2017. While complete financial information and operating data are not available, based on information currently available, we estimate the following:

These preliminary estimates have been prepared by, and are the responsibility of, our management. Our independent registered public accounting firm, Ernst& Young LLP, has not audited or reviewed, and does not express an opinion with respect to, these estimates. Actual results and financial data as of December31, 2017 may differ from the above estimates due to the completion of our closing procedures with respect to the fiscal year ended December31, 2017, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized. We expect to complete our closing procedures with respect to the fiscal year ended December31, 2017 after this offering is consummated. Accordingly, our financial statements as of and for the fiscal year ended December31, 2017 will not be available until after this offering is completed.

The information provided in this Item 2.02 of this Current Report on Form8-K shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

On January23, 2018, Five Prime filed with the a preliminary prospectus supplement in connection with a proposed public offering of shares of Five Prime’s common stock. The preliminary prospectus supplement contains an updated description of certain aspects of Five Prime’s business. Accordingly, Five Prime is filing this information with this Current Report on Form 8-K for the purpose of updating the description of certain aspects of its business from the disclosure contained in Five Prime’s prior filings with the SEC, including the Five Prime’s most recent Annual Report on Form 10-K for the year ended December31, 2016, filed with the SEC on February24, 2017. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

2

FIVE PRIME THERAPEUTICS INC Exhibit
EX-99.1 2 d524382dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1,…
To view the full exhibit click here

About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)

Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).